NCT06448793Completed
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 650 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 25 Nov 2024
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Lung cancer
- NCT number
- NCT06448793
What you commit to
- Study type: Observational
- Participants enrolled: 650
- From 25 Nov 2024 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
Other
- Patients
- Not willing to be audio-recorded during the interview
- Physicians
- Not willing to be audio-recorded during the interview
Who the study is looking for
- Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
- Physicians
- Resident of the US, Germany, or Japan
- Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
- Treated at least three new patients with resectable NSCLC in the past year
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evidera Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.